Chrysea
Chrysea is a Dublin-based biotechnology company developing clinically-supported longevity interventions, commercializing its lead product Sprevive (a high-purity spermidine complex) through US healthcare practitioners and pharmacies via an exclusive partnership with nuBioAge.
- Company typePrivate
- Founded2019
- HeadquartersDublin, Ireland
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Chrysea does
Chrysea is a Dublin, Ireland-based biotechnology company founded in 2019 that develops nutritional interventions supported by clinical research for anti-aging and longevity applications. The company operates with a 1-10 person team and is privately held. Its core technology platform combines proprietary synthetic biology and biopharmaceutical development capabilities, significantly strengthened by the February 2024 acquisition of Rodon Biologics from Iberfar Group, which brought over 20 years of biomanufacturing and protein engineering experience into the company.
Chrysea's lead commercial product is Sprevive, a high-purity spermidine complex positioned as a bridge between longevity science and evidence-based clinical application. The product carries GRAS recognition and standardized dosing. In May 2026, Chrysea entered an exclusive US commercialization partnership with nuBioAge to distribute Sprevive through healthcare practitioners and pharmacies, shifting the company's go-to-market from wellness supplements toward clinician-guided longevity care. Concurrently, Chrysea is conducting a clinical study with Mount Sinai researchers evaluating Sprevive's effects on immune and metabolic function, intended to underpin evidence-based clinical claims.
The business model is built on clinical-channel distribution of proprietary longevity nutraceuticals rather than direct-to-consumer sales. Chrysea's primary customer segment is US healthcare practitioners and pharmacies reached through its nuBioAge distribution partner. The company does not publicly disclose pricing, revenue, or funding. Beyond Sprevive, the Rodon Biologics platform provides capability breadth in biomanufacturing, protein engineering, and sustainable product development, suggesting a longer-term ambition to expand into a broader bioproducts portfolio, though current monetization is concentrated in a single product line.
Chrysea firmographics
Firmographics- Name
- Chrysea
- Website
- https://chrysealabs.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Chrysea is a Dublin-based biotechnology company developing clinically-supported longevity interventions, commercializing its lead product Sprevive (a high-purity spermidine complex) through US healthcare practitioners and pharmacies via an exclusive partnership with nuBioAge.
- Ownership category
- akta.pro rank
Chrysea industry classification
Industry- Product category
- Longevity Biopharmaceuticals
- NAICS
- Medicinal and Botanical Manufacturing (325411)
- SIC
- Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Male Reproductive & Sexual Medicine (Andrology) (HLAKAOAD)
Keywords
Where Chrysea is headquartered
LocationHeadquarters
- HQ city
- Dublin
- HQ country
- Ireland
- HQ region
- Europe
Markets served
Chrysea business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Personnel, Marketing or Sales
Distribution channels1 record
Chrysea product offering
Product offeringCore offering
Chrysea develops and commercializes high-purity spermidine-based nutritional interventions targeting aging and longevity. Through its acquired biomanufacturing arm Rodon Biologics, the company produces Sprevive, a proprietary high-purity spermidine complex, which it distributes to healthcare practitioners and pharmacies for clinician-guided care.
Product overview
Chrysea is a biotechnology company operating with a multi-product portfolio focused on synthetic biology and biopharmaceutical development. The company operates through acquired capabilities (Rodon Biologics, bringing biomanufacturing and protein engineering expertise) and proprietary product development (Sprevive, a high-purity spermidine complex for longevity care). The portfolio spans wellness supplements transitioning toward clinician-guided clinical applications, supported by Mount Sinai research partnerships.
Differentiator
Problem solved
Functional benefit
Brands
- Sprevive: A high-purity spermidine complex developed for longevity and clinical applications, positioned as a bridge between longevity science and evidence-based clinical care.
Products and services
- Sprevive A proprietary high-purity spermidine complex developed as a nutritional intervention for aging and longevity, distributed to healthcare practitioners and pharmacies for clinician-guided patient care.
Companies that use Chrysea
Customer profileSegments1 record
Ideal customer profiles1 record
Chrysea technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Chrysea partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- nuBioAgecorePartnership to bring Sprevive (high-purity spermidine complex) into US clinical settings. nuBioAge received exclusive rights to commercialize the product through healthcare practitioners and pharmacies, representing a shift from wellness supplements toward clinician-guided longevity care.
- Mount SinaiminorChrysea is conducting a study with Mount Sinai researchers to explore how Sprevive supports immune and metabolic function, positioning the product as a bridge between longevity science and evidence-based clinical application.
- Rodon BiologicscoreChrysea acquired Rodon Biologics from Iberfar Group to strengthen capabilities in synthetic biology and biopharmaceutical development. The acquisition enables expansion in biomanufacturing, protein engineering, and sustainable product development.
Recent moves5 records
Expansion highlights5 records
Chrysea competitors and assessment
Company assessmentDirect peers
- Elysium Health: Elysium Health develops and commercializes clinically-validated longevity supplements (e.g., NAD+ boosters) sold through both DTC and clinician channels. It is the closest analogue to Chrysea's positioning of a science-backed, clinically-tested longevity bioactive sold to health-conscious consumers and practitioners.
- Tally Health: Tally Health markets longevity-focused supplements and biological-age testing directly to consumers and partners. It overlaps with Chrysea in the science-led longevity nutraceutical category targeting the same health-conscious, longevity-curious buyer.
- Insilico Medicine: Insilico Medicine is a longevity and aging-disease biotech combining AI-driven discovery with internal development pipelines. It is comparable to Chrysea as a science-first longevity company pursuing clinically-validated interventions rather than commodity supplements.
- BioAge Labs: BioAge Labs develops therapeutics targeting the biology of aging, including metabolic and immune function pathways relevant to longevity. It shares Chrysea's positioning at the intersection of longevity science, immune/metabolic mechanisms, and clinical development.
- Juvenescence: Juvenescence is a longevity-focused biotech that develops and invests in compounds targeting aging biology. It is comparable as a multi-program longevity company pursuing clinically-validated aging interventions rather than generic supplements.
- Longeveron: Longeveron is a clinical-stage biotech developing cellular therapies for aging-related and rare diseases. It overlaps with Chrysea in the clinical longevity therapeutics space targeting biological aging mechanisms.
- Human Longevity Inc. Human Longevity Inc. combines longevity-focused health intelligence, diagnostics, and clinical programs. It is comparable to Chrysea as a science-driven longevity company building premium clinical channels around aging biology.
Broad incumbents
- Ginkgo Bioworks: Ginkgo Bioworks is a large synthetic biology platform that programs cells for bioactives, flavors, and industrial biotech. It overlaps with Chrysea on the synthetic biology and biomanufacturing capability stack acquired via Rodon Biologics.
- Codexis: Codexis develops engineered enzymes and biomanufacturing processes for pharmaceuticals and sustainable chemicals. It is comparable to Chrysea/Rodon on the protein engineering and biomanufacturing capability dimension, though serving pharma and industrial customers rather than direct longevity consumers.
- Novonesis (Novozymes): Novonesis is a global industrial biotechnology leader in enzyme and microbial fermentation-based manufacturing. It is comparable to Chrysea on the fermentation-driven biomanufacturing and protein engineering capability axis, operating at much larger scale across multiple end markets.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
Chrysea social profiles
Digital presenceChrysea financial estimates
Financial estimateRevenue estimate
Valuation estimate
Chrysea leadership team
Management profileNumber of profiles
Profiles2 records
Chrysea subsidiaries and ownership
Company hierarchySubsidiaries1 record
Chrysea funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Chrysea M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Chrysea
What does Chrysea do?
Chrysea develops and commercializes high-purity spermidine-based nutritional interventions targeting aging and longevity. Through its acquired biomanufacturing arm Rodon Biologics, the company produces Sprevive, a proprietary high-purity spermidine complex, which it distributes to healthcare practitioners and pharmacies for clinician-guided care.
Is Chrysea a public or private company?
Chrysea is a private company. It is classified as unknown and is currently operating.
When was Chrysea founded?
Chrysea was founded in 2019. It employs 1 to 10 people.
Where is Chrysea based?
Chrysea is headquartered in Dublin, Ireland, in the Europe region.
Who are Chrysea's main competitors?
Direct peers on record are Elysium Health, Tally Health, Insilico Medicine, BioAge Labs, Juvenescence, Longeveron and Human Longevity Inc.. Broad incumbents are Ginkgo Bioworks, Codexis and Novonesis (Novozymes).
Does Chrysea have an API?
No public API is recorded for Chrysea.
What industry is Chrysea in?
Chrysea's product category is Longevity Biopharmaceuticals. Its primary akta.pro industry code is HLAKAOAD, Male Reproductive & Sexual Medicine (Andrology). Its NAICS code is 325411 and its SIC code is 2833.